Differential effects of exogenous interleukin-10 on cardiac allograft survival - Inhibition of rejection by recipient pretreatment reflects impaired host accessory cell function

被引:29
作者
Li, W
Fu, FM
Lu, LN
Narula, SK
Fung, JJ
Thomson, AW
Qian, SG
机构
[1] Univ Pittsburgh, Med Ctr, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA
[3] Schering Plough Corp, Res Inst, Dept Immunol, Kenilworth, NJ 07033 USA
关键词
D O I
10.1097/00007890-199911150-00029
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background, There have been conflicting reports of the influence of exogenous mammalian interleukin (IL)-10 on immune reactivity. These findings may reflect the pleiotropic effects of IL-10 on the functions of antigen-presenting cells and immune effector cells. The purpose of this study was to extend observations of the influence of the cytokine on organ allograft survival and to investigate its effects on the function of accessory and immune effector cells in a mouse cardiac transplant model. Methods. C3H (H2(k)) recipients of heterotopic vascularized B10 (H-2(b)) heart allografts were treated with recombinant (r) mouse IL-10 over a wide range of doses (0.2-200 mu g/day), either before the transplant (days -3, -2, -1), peri-operatively (days -1, 0, 1), or after the transplant (days 0-6), Anti-donor cytotoxic T lymphocyte activity of host spleen and graft-infiltrating cells, and circulating complement-dependent cytotoxic antibody titers were determined by isotope release assays. Mixed leukocyte reactions were used to determine the influence of IL-10 on the function of antigen-presenting cells and allogeneic responder T cells. Results. Recipient pre-transplant administration of IL-10 (days -3, -2, -1) prolonged graft survival at all doses tested. Donor pretreatment with IL-10 (25 mu g/ day; days -3, -2, -1) was also effective, but less. A pre-transplant or perioperative course of IL-10, however, did not significantly affect the immunosuppressive action of tacrolimus given on days 0-6. If given only after the transplant, IL-10 either had no effect on graft survival or (at high dosage) accelerated rejection and prevented the immunosuppressive effect of cyclosporine, Pretransplant treatment of graft recipients with IL-10 reduced splenic anti-donor cytotoxic T lymphocyte activity and the incidence of graft-infiltrating CD8(+) cells. There was no significant effect on circulating alloantibody titers, MLR assays revealed that preincubation of responder cells, but not stimulator spleen cells with IL-10, inhibited T cell proliferation, whereas addition of IL-10 after the start of culture modestly enhanced proliferation, Preincubation of purified T responders with IL-10 showed no inhibitory effect, Conclusion. The modest and opposing effects of exogenous IL-10 on organ allograft survival are dependent on timing and dosage, Recipient pretreatment prolongs graft survival. This finding, together with the MLR results, suggest that IL-10 inhibits the function of host immune accessory cells and that the direct pathway of alloantigen presentation may be less susceptible to inhibition by IL-10.
引用
收藏
页码:1402 / 1409
页数:8
相关论文
共 41 条
[31]   INTERLEUKIN-10 IS A POTENT GROWTH AND DIFFERENTIATION FACTOR FOR ACTIVATED HUMAN LYMPHOCYTES-B [J].
ROUSSET, F ;
GARCIA, E ;
DEFRANCE, T ;
PERONNE, C ;
VEZZIO, N ;
HSU, DH ;
KASTELEIN, R ;
MOORE, KW ;
BANCHEREAU, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (05) :1890-1893
[32]   STIMULATION OF CYTOLYTIC ACTIVITY BY INTERLEUKIN-10 [J].
SCHWARZ, MA ;
HAMILTON, LD ;
TARDELLI, L ;
NARULA, SK ;
SULLIVAN, LM .
JOURNAL OF IMMUNOTHERAPY, 1994, 16 (02) :95-104
[33]  
Steinbrink K, 1997, J IMMUNOL, V159, P4772
[34]   IL-10 INHIBITS APOPTOTIC CELL-DEATH IN HUMAN T-CELLS STARVED OF IL-2 [J].
TAGA, K ;
CHERNEY, B ;
TOSATO, G .
INTERNATIONAL IMMUNOLOGY, 1993, 5 (12) :1599-1608
[35]  
TAN JQ, 1993, J IMMUNOL, V151, P4545
[36]   INTERLEUKIN-10 - A NOVEL STIMULATORY FACTOR FOR MAST-CELLS AND THEIR PROGENITORS [J].
THOMPSONSNIPES, LA ;
DHAR, V ;
BOND, MW ;
MOSMANN, TR ;
MOORE, KW ;
RENNICK, DM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (02) :507-510
[37]   ISOLATION AND EXPRESSION OF HUMAN CYTOKINE SYNTHESIS INHIBITORY FACTOR CDNA CLONES - HOMOLOGY TO EPSTEIN-BARR-VIRUS OPEN READING FRAME BCRFI [J].
VIEIRA, P ;
DEWAALMALEFYT, R ;
DANG, MN ;
JOHNSON, KE ;
KASTELEIN, R ;
FIORENTINO, DF ;
DEVRIES, JE ;
RONCAROLO, MG ;
MOSMANN, TR ;
MOORE, KW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (04) :1172-1176
[38]   INTERLEUKIN-10 INHIBITS B7 AND INTERCELLULAR-ADHESION MOLECULE-1 EXPRESSION ON HUMAN MONOCYTES [J].
WILLEMS, F ;
MARCHANT, A ;
DELVILLE, JP ;
GERARD, C ;
DELVAUX, A ;
VELU, T ;
DEBOER, M ;
GOLDMAN, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (04) :1007-1009
[39]   A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy [J].
Wissing, KM ;
Morelon, E ;
Legendre, C ;
DePauw, L ;
LeBeaut, A ;
Grint, P ;
Maniscalki, M ;
Ickx, B ;
Vereerstraeten, P ;
Chatenoud, L ;
Kreis, H ;
Goldman, M ;
Abramowicz, D .
TRANSPLANTATION, 1997, 64 (07) :999-1006
[40]   INTRAGRAFT EXPRESSION OF IL-10 MESSENGER-RNA - A NOVEL CORRELATE OF RENAL-ALLOGRAFT REJECTION [J].
XU, GP ;
SHARMA, VK ;
LI, B ;
BOLOGA, R ;
LI, Y ;
MOURADIAN, J ;
WANG, J ;
SERUR, D ;
RAO, V ;
STENZEL, KH ;
SUTHANTHIRAN, I .
KIDNEY INTERNATIONAL, 1995, 48 (05) :1504-1507